SOLICITATION NOTICE
B -- Determination of Telomere length in 744 samples
- Notice Date
- 6/24/2010
- Notice Type
- Presolicitation
- NAICS
- 621511
— Medical Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-100114-KM
- Archive Date
- 7/24/2010
- Point of Contact
- Karri L. Mares, Phone: 3014357774, Caren N Rasmussen, Phone: (301) 402-4509
- E-Mail Address
-
maresk@mail.nih.gov, cr214i@nih.gov
(maresk@mail.nih.gov, cr214i@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- General Information Document Type: Presolicitation Notice Solicitation Number: NCI-100114-KM Proposed Posted Date: 6/24/10 Proposed Response Date: 7/9/10 11AM EST Classification Code: B—Special Studies and analysis – not R&D NAICS Code: 621511 Medical Laboratories Business Size Standard: $13.5 million. Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Boulevard, EPS Suite 600, Room 6070, Rockville, MD 20852, UNITED STATES. Description The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), plans to procure on a sole source basis services from Brigham and Women’s Hospital, Channing Laboratory, 181 Longwood Avenue, Boston, MA 02115 This acquisition will be processed in accordance with simplified acquisition procedures in FAR Part 13.106-1(b)(1). The North American Industry Classification System code is 621511 and the business size standard is $13.5 million. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. Period of Performance: Performance shall be for eight (8) months from date of award. The Division of Cancer Epidemiology and Genetics (DCEG) is an intramural research program of the National Cancer Institute (NCI), National Institutes of Health (NIH) that conducts population and multidisciplinary research to discover the genetic and environmental determinants of cancer and new approaches to cancer prevention. Telomeres are non-coding DNA repeats at chromosome ends that help preserve genomic structural integrity. Telomeric repeats progressively shorten with each cell division and, when critically short, they induce normal cells to undergo cellular senescence or apoptosis. Malignant cells, lacking a normal DNA damage response (e.g., loss of wild type TP53 ), can bypass this crisis state and continue to divide. Therefore, critical telomere shortening may result in genetic instability in these cells. Many case-control studies have observed an association between shorter telomeres in constitutional DNA and bladder, breast, head and neck, lung, and renal cell cancers. The contractor shall determine telomere length in 240 pre-diagnostic samples from women with ovarian cancer and 240 matched controls, 204 tumor tissues, and an additional 60 quality control samples. Brigham & Women’s Hospital has one of a very limited number of laboratories that currently has an operating telomere assay. This is the only assay that allows high throughput measurement of telomere length in a 384-well format using very little amount of DNA. DCEG has made significant investments in collecting the limited tissues in epidemiological studies. Several molecular efforts need to be performed from DNA extracted from the limited tissue. At the same time, the large numbers of cases and controls in DCEG’s epidemiological studies require highly standardized high-throughput assays to make sure that the results are comparable and obtained in a timely fashion. The other techniques available (Southern blot, FISH) require large amounts of DNA that are not available within these studies and lack high-throughput capabilities rendering these techniques unsuitable for the proposed epidemiological studies. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI Office of Acquisitions on or before 11:00 AM EST on July 9, 2010 11:00 a.m. EST. No electronic capability statements will be accepted (i.e. email or fax). An original and one copy must be sent to the NCI Office of Acquisitions at the address stated above. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Karri Mares, Contract Specialist, at maresk@mail.nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference solicitation number NCI-­­100114-KM on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-100114-KM/listing.html)
- Record
- SN02187705-W 20100626/100624235518-a82fdf7d71a83581eb33d57a52f75517 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |